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Provenance: Commissioned; not externally peer reviewed alarming levels of resistance to macrolide and fluoroquinolone antimicrobials [8] . Syndromic treatment of symptomatic urethritis, the norm in both high-and low-income settings, has actually limited the use of antimicrobials. Paradoxically, improved aetiological diagnosis will result in increased treatment, and multidrug resistance, because asymptomatic infections will also be detected and treated. New guidelines should recommend diagnostic test and treatment strategies for urethritis and M. genitalium that minimise the risk of AMR.
Challenges like these require real-world knowledge, and we believe that insights from social science methodology are critical for illuminating possible solutions. We are delighted that this Collection includes a qualitative study from Kipruto Chesang and colleagues, in which the authors describe many of the challenges that healthcare providers (HCPs) worldwide face in delivering STI care [9] . The authors interviewed 87 HCPs working in HIV care centres across Kenya. Their analysis shows strong HCP commitment to the provision of high-quality STI care but underscores the impact of stigma and culturally embedded gender roles. This study suggests that clinics often do not provide for the sexual and reproductive health needs of men and boys, even though their active engagement is essential for the sexual health of both women and men [10] . Chesang and colleagues also describe the day-to-day health service barriers of antimicrobial treatment failure, ascribed to resistance, insufficient training, and drug stockouts. In relation to the last point, Collection authors Stephen Nurse-Findlay and colleagues explore the origins of a vexing worldwide shortage of benzathine penicillin for the treatment of maternal syphilis, using country-level surveys and stakeholder interviews [11] . They find that local stock-outs are not just the result of demand-side under-procurement, but of supplyside inflexibility and market exits for this cheap, off-patent drug.
In more auspicious developments, digital technologies and newer diagnostics with simple requirements for specimen collection and transport are driving innovations in access to STI care. In this area, Collection authors Emma Wilson and colleagues evaluated the benefits of providing "e-STI testing and results" in a randomised controlled trial done in London, UK [12] . They used text messages to invite people to place an online order for self-sampling kits for chlamydia, gonorrhoea, syphilis and HIV. The e-STI testing and results intervention increased the proportion of people tested for STIs, and slightly increased the proportion diagnosed with any STI, compared with people sent a simple text message with information about the location of STI clinics. The researchers used multiple active methods to reach and engage their target group; therefore, to sustain the benefits of the e-STI testing intervention, these health promotion activities would need to continue. Even in times of economic austerity, e-STI testing should not be seen as a substitute for fully funded clinic-based services [13] .
Meanwhile, highly efficacious vaccines against human papillomaviruses and hepatitis B virus have demonstrated the benefits of innovation in vaccine development, and results in this Collection suggest that further innovation will not be wasted. Christine Johnston and colleagues' findings support the development of a vaccine against herpes simplex type 2 (HSV-2) as the next most promising vaccine priority [14] . In people with HSV-2 antibodies enrolled in epidemiological studies in the Americas and sub-Saharan Africa, just 3.7% had prevalent infection with more than one HSV-2 strain, indicating the effectiveness of naturally occurring protection.
Future progress in understanding the pathogenesis of STIs in women, who bear a large proportion of the world population's burden of STIs, will rely on the innovations of highthroughput molecular sequencing methods that have revealed the complexity of the vaginal microbiome. In a Perspective, Janneke van de Wijgert discusses what we now know about interrelationships between exogenous sexually transmitted bacterial pathogens, dysbiosis affecting the lactobacillus-dominated microbiome, and pathobionts, commensal bacteria with pathogenic potential [15] . However, improved understanding of the nature and properties of vaginal microbiomes will be required for the development of approaches for optimising vaginal health.
Successes in STI control require commitments to addressing the economic, social, cultural, and behavioural determinants of STIs. In the face of a widening spectrum of infectious agents that can be transmitted through sexual contact, as described in an Essay by Kyle Bernstein and colleagues, interdisciplinary action will be important to the development of effective interventions [16] . High-quality research is one of the solutions that, together with strengthened capacity, promotion of sexual rights and political commitment, can secure a future of effective STI prevention, diagnosis, and treatment.
